Kim Fox

1978–2024 年に発表

78
論文数
18,155
被引用数
61
h 指数
77
i10 指数

被引用数

Kim Fox の年別被引用数1979 年: 被引用 1 件1980 年: 被引用 4 件1981 年: 被引用 1 件1982 年: 被引用 3 件1983 年: 被引用 8 件1984 年: 被引用 7 件1985 年: 被引用 7 件1986 年: 被引用 2 件1987 年: 被引用 6 件1988 年: 被引用 13 件1989 年: 被引用 6 件1990 年: 被引用 14 件1991 年: 被引用 10 件1992 年: 被引用 15 件1993 年: 被引用 6 件1994 年: 被引用 8 件1995 年: 被引用 7 件1996 年: 被引用 18 件1997 年: 被引用 8 件1998 年: 被引用 12 件1999 年: 被引用 17 件2000 年: 被引用 29 件2001 年: 被引用 39 件2002 年: 被引用 31 件2003 年: 被引用 50 件2004 年: 被引用 80 件2005 年: 被引用 74 件2006 年: 被引用 91 件2007 年: 被引用 117 件2008 年: 被引用 79 件2009 年: 被引用 95 件2010 年: 被引用 84 件2011 年: 被引用 101 件2012 年: 被引用 107 件2013 年: 被引用 109 件2014 年: 被引用 98 件2015 年: 被引用 82 件2016 年: 被引用 99 件2017 年: 被引用 88 件2018 年: 被引用 58 件2019 年: 被引用 234 件2020 年: 被引用 237 件2021 年: 被引用 292 件2022 年: 被引用 294 件2023 年: 被引用 270 件2024 年: 被引用 389 件2025 年: 被引用 194 件2026 年: 被引用 16 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,135 件、この内訳の 19.2%イギリス: 引用元論文 576 件、この内訳の 9.7%イタリア: 引用元論文 410 件、この内訳の 6.9%中国: 引用元論文 347 件、この内訳の 5.9%カナダ: 引用元論文 303 件、この内訳の 5.1%ドイツ: 引用元論文 300 件、この内訳の 5.1%フランス: 引用元論文 250 件、この内訳の 4.2%オーストラリア: 引用元論文 223 件、この内訳の 3.8%オランダ: 引用元論文 201 件、この内訳の 3.4%スウェーデン: 引用元論文 192 件、この内訳の 3.3%スペイン: 引用元論文 169 件、この内訳の 2.9%スイス: 引用元論文 130 件、この内訳の 2.2%
0%19.2%その他 28.3%

分野

  • Medicine85.1%
  • Biochemistry, Genetics and Molecular Biology5%
  • Engineering2.1%
  • Neuroscience1.1%
  • Nursing0.9%
  • Computer Science0.9%
  • その他4.9%

トピック

  • Blood Pressure and Hypertension Studies7%
  • Cardiac Imaging and Diagnostics5.4%
  • Acute Myocardial Infarction Research5%
  • Heart Rate Variability and Autonomic Control4.4%
  • Heart Failure Treatment and Management3.8%
  • Heart rate and cardiovascular health3.5%
  • その他70.9%

共著者

全論文

検索で開く
  1. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Masao Ishii, Stevo Julius, Yoshihiko Kanno, Sverre E. Kjeldsen, John B. Kostis, Kizuku Kuramoto, Jan Lanke, Edmund J. Lewis, Julia B. Lewis, Michel Lièvre, Lars Lindholm, Stephan Lueders, Stephen MacMahon, Giuseppe Mancia, Masunori Matsuzaki, Maria H. Mehlum, Steven Nissen, Hiroshi Ogawa, Toshio Ogihara, Takayoshi Ohkubo, Christopher R. Palmer, Anushka Patel, Marc Allan Pfeffer, Bertram Pitt, Neil R Poulter, Hiromi Rakugi, Gianpaolo Reboldi, Christopher M. Reid, Giuseppe Remuzzi, Piero Ruggenenti, Takao Saruta, Joachim Schrader, Robert W. Schrier, Peter Sever, Peter Sleight, Jan A. Staessen, Hiromichi Suzuki, Lutgarde Thijs, Kenji Ueshima, Seiji Umemoto, Wiek H. van Gilst, Paolo Verdecchia, Kristian Wachtell, Paul K. Whelton, Lindon Wing, Yoshiki Yui, Salim Yusuf, Alberto Zanchetti, Zhen‐Yu Zhang, Craig S. Anderson, Colin Baigent, Barry M. Brenner, Rory Collins, Dick de Zeeuw, Jacobus Lubsen, Ettore Malacco, Bruce Neal, Vlado Perkovic, Anthony Rodgers, Peter M. Rothwell, Gholamreza Salimi-Khorshidi, Johan Sundström, Fiona Turnbull, Giancarlo Viberti, Ji‐Guang Wang, John Chalmers, Koon Teo, Carl J. Pepine, Barry R. Davis - The Lancet 2021 被引用: 1,001

  2. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rury R. Holman, Yutaka Imai, Masao Ishii, Stevo Julius, Yoshihiko Kanno, Sverre E. Kjeldsen, John B. Kostis, Kizuku Kuramoto, Jan Lanke, Edmund J. Lewis, Julia B. Lewis, Michel Lièvre, Lars Lindholm, Stephan Lueders, Stephen MacMahon, Giuseppe Mancia, Masunori Matsuzaki, Maria H. Mehlum, Steven Nissen, Hiroshi Ogawa, Toshio Ogihara, Takayoshi Ohkubo, Christopher R. Palmer, Anushka Patel, Marc Allan Pfeffer, Bertram Pitt, Neil R Poulter, Hiromi Rakugi, Gianpaolo Reboldi, Christopher M. Reid, Giuseppe Remuzzi, Piero Ruggenenti, Takao Saruta, Joachim Schrader, Robert W. Schrier, Peter Sever, Peter Sleight, Jan A. Staessen, Hiromichi Suzuki, Lutgarde Thijs, Kenji Ueshima, Seiji Umemoto, Wiek H. van Gilst, Paolo Verdecchia, Kristian Wachtell, Paul K. Whelton, Lindon Wing, Mark Woodward, Yoshiki Yui, Salim Yusuf, Alberto Zanchetti, Zhen‐Yu Zhang, Craig S. Anderson, Colin Baigent, Barry M. Brenner, Rory Collins, Dick de Zeeuw, Jacobus Lubsen, Ettore Malacco, Bruce Neal, Vlado Perkovic, Anthony Rodgers, Peter M. Rothwell, Gholamreza Salimi-Khorshidi, Johan Sundström, Fiona Turnbull, Giancarlo Viberti, Ji‐Guang Wang, John Chalmers, Barry R. Davis ほか 2 名 - The Lancet 2021 被引用: 321

  3. Resting Heart Rate in Cardiovascular Disease

    著者: , , , , , , , , , - Journal of the American College of Cardiology 2007 被引用: 1,063

  4. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study

    著者: , , , , , , , , , - The Lancet 2016 被引用: 483

  5. Ticagrelor in Patients with Stable Coronary Disease and Diabetes

    著者: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 362

  6. Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2021 被引用: 161

  7. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

    著者: - The Lancet 2003 被引用: 2,153

  8. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

    著者: , , , , - The Lancet 2008 被引用: 1,095

  9. Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure

    著者: , , , , , - New England Journal of Medicine 2014 被引用: 482

  10. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , R Estacio, Robert Fagard, Kim Fox, Takahiro Fukui, Ajay Gupta, Rury R. Holman, Y. Imai, Masao Ishii, Stevo Julius, Yoshihiko Kanno, Sverre E. Kjeldsen, John B. Kostis, K Kuramoto, Jan Lanke, Edmund J. Lewis, Jeff Lewis, Michel Lièvre, Lars Lindholm, Stephan Lueders, Stephen MacMahon, G. Mancia, M Matsuzaki, Maria H. Mehlum, Steven Nissen, Hiroshi Ogawa, Toshio Ogihara, Takayoshi Ohkubo, C. Palmer, Anushka Patel, Carl J. Pepine, Michael Pfeffer, N. Poulter, Hiromi Rakugi, Gianpaolo Reboldi, Christopher M. Reid, Giuseppe Remuzzi, Piero Ruggenenti, T Saruta, Joachim Schrader, Robert W. Schrier, Peter S. Sever, Peter Sleight, Jan A. Staessen, Hiromichi Suzuki, Lutgarde Thijs, Kenji Ueshima, Seiji Umemoto, Wiek H. van Gilst, Paolo Verdecchia, Kristian Wachtell, Paul K. Whelton, L. Wing, Mark Woodward, Yoshiaki Yui, Salim Yusuf, Alberto Zanchetti, Z Y Zhang, Craig S. Anderson, Colin Baigent, Brenner Bm, Richard Collins, Dick de Zeeuw, Jacobus Lubsen, Ettore Malacco, Bruce Neal, Vlado Perkovic, Bertram Pitt, Anthony Rodgers, Peter M. Rothwell, Gholamreza Salimi-Khorshidi ほか 4 名 - The Lancet Oncology 2021 被引用: 104

  11. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francisco Padrón, R. Passi, Jay Stone, Michael Pursley, Michael D'Urso, Timothy J. Gardner, James Bennett, Khaled Nour, Satinder Saini, Wenwu Zhang, Dharam J. Kumbhani, Dustin Thomas, Dominick J. Angiolillo, Barry Bertolet, Amaury Roman-Miranda, Robert Black, Ramin Manshadi, Carlos Vaca, Antonio Blanco, Mark Napoli, David Brabham, Ayim Akyea-Djamson, Pratik Desai, Sudhir Prasada, Ajit S Khaira, Leslie B. Forgosh, Ira Lieber, Guillermo E. Umpierrez, Dinesh Singal, Juan Luis Londoño, Neil Fraser, Jose Ruiz, Damaris Vega, Lilia Rodriguez, Christopher Brown, Faizullah Syed, Guarav Aggarwala, William Eaves, Michael Foster, Dinesh Gupta, David Avino, Wail Asfour, Glen Tonnessen, Xue‐Qiao Zhao, Narendra Singh, Andrew Brockmyre, Norman Lepor, Nicolas W. Shammas, David R. Blick, Steven Hearne, John Prodafikas, Edgar S. Carell, Mark Izzo, Amin H. Karim, Bosh Zakhary, Mahmoud Atieh, Steven B. Leichter, Charles Meadows, David R. Hotchkiss, Mazen Abu-Fadel, Alan Wiseman, Jeffrey Bander, Mahesh Shah, Subhash Banerjee, Ricky Ganim, Karen S Sopko, Misal Khan, Ramon L. Lloret, Troy Weirick, Rajendra H. Mehta ほか 1,247 名 - The Lancet 2019 被引用: 210

  12. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry

    著者: , , , , , , , , , , , , , , , , - European Heart Journal 2019 被引用: 102

  13. A 'diamond' approach to personalized treatment of angina

    著者: , , , , , , , , , - Nature Reviews Cardiology 2017 被引用: 169

  14. Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients

    著者: , , , , , , , , , , , , , , , , , , , - Stroke 2014 被引用: 109

  15. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

    著者: , , , , , - The Lancet 2008 被引用: 788

  16. International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study

    著者: , , , , , , , , , - Circulation 2021 被引用: 61

  17. Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease

    著者: , , , , , , , , , , , - JAMA Internal Medicine 2014 被引用: 146

  18. Heart rate reduction in coronary artery disease and heart failure

    著者: , - Nature Reviews Cardiology 2016 被引用: 109

  19. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry

    著者: , , , , , , , , , - European Journal of Preventive Cardiology 2014 被引用: 77

  20. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities

    著者: , , , , , , , , , , , , , - European Journal of Preventive Cardiology 2021 被引用: 38

  21. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

    著者: , , , , - The Lancet 2006 被引用: 514

  22. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology

    著者: , , , , , , , , - European Heart Journal 2006 被引用: 391

  23. Anti-anginal drugs–beliefs and evidence: systematic review covering 50 years of medical treatment

    著者: , , , , , , , , , , - European Heart Journal 2018 被引用: 101

  24. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , - The Lancet 2020 被引用: 75